2.11% -0.6002

BridgeBio Pharma Inc (BBIO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt BBIO? Forum Prognose

Warum fällt BridgeBio Pharma Inc-Aktie (BBIO)?

Wir haben während der Handelssitzung 2024-04-12 einen Rückgang der Aktie BridgeBio Pharma Inc (BBIO) um 5.39% festgestellt. Obwohl dies auf normale Volatilität oder verschiedene interne und externe Faktoren zurückzuführen sein kann, beachten Sie bitte, dass wir die Situation aktiv beobachten und so schnell wie möglich zeitnahe Updates bereitstellen!

2024-03-04:

BridgeBio Pharma Inc (BBIO) stock declined by 9.19% due to the announcement of a $250 million public offering.

Offering details: The offering, totaling $250 million of shares of its common stock, aims to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares. All shares in the proposed offering will be sold by BridgeBio.
Reasons for the Decline: The offering news likely caused the stock price to pull back due to dilution concerns. When the company issues new shares, it can dilute the ownership stake of existing shareholders, leading to a decrease in the stock price. Investors may also be cautious about the potential impact of the offering on BridgeBio's financials and future growth prospects.

2023-06-15:

BBIO's stock fell 8.11% following a cautious note by JPMorgan Chase regarding the biotech's experimental treatment of symptomatic transthyretin amyloidosis cardiomyopathy, or ATTR-CM, known as acoramidis. JPMorgan's team considered this a "high-risk" event due to the well-documented difficulty in treating patients with this condition.

https://www.fool.com/investing/2023/06/15/why-bridgebio-pharma-stock-is-plunging-today/